Provided by Tiger Fintech (Singapore) Pte. Ltd.

Shuttle Pharmaceuticals Inc

0.1748
+0.00080.46%
Post-market: 0.1714-0.0034-1.95%19:59 EDT
Volume:916.08K
Turnover:158.63K
Market Cap:1.92M
PE:-0.05
High:0.1840
Open:0.1840
Low:0.1647
Close:0.1740
Loading ...

Shuttle Pharma Provides Corporate Update

THOMSON REUTERS
·
16 May

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

THOMSON REUTERS
·
09 May

Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

GlobeNewswire
·
22 Apr

Shuttle Pharmaceuticals Files Provisional US Patent to Treat Prostrate Cancer

MT Newswires Live
·
11 Apr

BRIEF-Shuttle Pharmaceuticals Files Provisional Patent Application For PSMA Ligand Conjugates To Treat Prostate Cancer

Reuters
·
11 Apr

Shuttle Pharmaceuticals- Files Provisional Patent Application for Psma Ligand Conjugates to Treat Prostate Cancer

THOMSON REUTERS
·
11 Apr

Shuttle Pharmaceuticals files provisional patent application with USPTO

TIPRANKS
·
11 Apr

Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

GlobeNewswire
·
11 Apr

Shuttle Pharmaceuticals Holdings Inc - on March 21, Enters Consulting Agreement With Bowery Consulting - SEC Filing

THOMSON REUTERS
·
26 Mar

Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

THOMSON REUTERS
·
14 Mar

BRIEF-Shuttle Pharmaceuticals Holdings Offers Up To 10,000,000 Shares Of Common Stock

Reuters
·
05 Mar

Shuttle Pharmaceuticals Holdings Inc - Offering up to 10,000,000 Shares of Common Stock

THOMSON REUTERS
·
05 Mar

BRIEF-Shuttle Pharmaceuticals Holdings Enters $2 Million Revolving Loan Agreement

Reuters
·
01 Mar

Shuttle Pharmaceuticals Holdings Inc - Enters $2 Million Revolving Loan Agreement

THOMSON REUTERS
·
01 Mar

Shuttle Pharmaceuticals FY24 EPS $(3.30) Vs $(3.53) YoY

Benzinga
·
26 Feb

Shuttle Pharma Provides Corporate Update and Reports 2024 Results

GlobeNewswire
·
26 Feb

Shuttle reaches milestone in enrollment for Phase 2 trial of Ropidoxuridine

TIPRANKS
·
21 Jan

Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma

THOMSON REUTERS
·
21 Jan

Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

GlobeNewswire
·
21 Jan

Shuttle Pharmaceuticals enters into sponsored research agreement with UCSF

TIPRANKS
·
19 Dec 2024